Mirum Pharmaceuticals, Inc.
MIRM
株式のランク
#3346
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
株価
$80.17
最終同期: 2026-10-16
時価総額
$5.21B
変化（1日）
-2.69%
変化（1年）
9.03%
国
US
取引 Mirum Pharmaceuticals, Inc. (MIRM)
カテゴリー
Healthcare
Mirum Pharmaceuticals, Inc.（MIRM）のEPS
June 2026 時点のEPS TTM: $-14.56
Mirum Pharmaceuticals, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-14.56です。2023年末には、EPSは$-4.00で、2022年のEPS$-4.01と減少でした。
Mirum Pharmaceuticals, Inc.のEPS履歴（2018から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-14.56 | 687.03% |
| 2024 | $-1.85 | -53.75% |
| 2023 | $-4.00 | -0.25% |
| 2022 | $-4.01 | 44.77% |
| 2021 | $-2.77 | -32.27% |
| 2020 | $-4.09 | 78.60% |
| 2019 | $-2.29 | 205.33% |
| 2018 | $-0.75 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -218.96% |
US
|
|
| $-7.98 | -45.19% |
US
|
|
| $-5.29 | -63.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -290.52% |
NL
|
